Compare XBIO & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIO | SBFM |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 7.2M |
| IPO Year | N/A | N/A |
| Metric | XBIO | SBFM |
|---|---|---|
| Price | $2.41 | $1.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 47.5K | ★ 66.6K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,858,935.00 | ★ $37,323,742.00 |
| Revenue This Year | $1.99 | $10.26 |
| Revenue Next Year | $20.00 | $32.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.30 | 13.24 |
| 52 Week Low | $2.20 | $1.17 |
| 52 Week High | $13.93 | $3.90 |
| Indicator | XBIO | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 40.78 | 34.27 |
| Support Level | $2.31 | $1.43 |
| Resistance Level | $2.64 | $1.49 |
| Average True Range (ATR) | 0.18 | 0.06 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 31.65 | 0.00 |
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.